Chronic kidney disease trials recruiting in Ohio

All Chronic kidney disease trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
  NCT06830629 · Phase: Phase 2 · Ages: 18 Years to 68 Years · Sex: All (male and female) · Ohio: Cleveland, Columbus
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Canton, Cincinnati, Columbus
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
  NCT07222917 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
  NCT07268638 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
  NCT06933472 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Ohio: Toledo
• A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
  NCT06712654 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Toledo
• A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
  NCT03619850 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Akron
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
  NCT07107945 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Maumee
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
  NCT03633708 · Phase: Phase 3 · Ages: 0 Years to 18 Years · Sex: All (male and female) · Ohio: Cincinnati, Cleveland
• BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
  NCT06741072 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Columbus
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Ohio: Akron, Barberton, Beavercreek, Belpre
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
  NCT06712407 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Ferric Citrate and Chronic Kidney Disease in Children
  NCT04741646 · Phase: Phase 2 · Ages: 6 Years to 18 Years · Sex: All (male and female) · Ohio: Cincinnati, Columbus
• Kidney Precision Medicine Project
  NCT04334707 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
  NCT06694558 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
  NCT07494045 · Phase: Phase 2 · Ages: 1 Month to 17 Years · Sex: All (male and female) · Ohio: Columbus
• Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
  NCT04634916 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Toledo
• Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
  NCT05027906 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Ohio: Cincinnati
• Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
  NCT06217302 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cleveland
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
  NCT07498335 · Phase: Phase 3 · Ages: 2 Years to 18 Years · Sex: All (male and female) · Ohio: Cincinnati
• Transformative Research in Diabetic Nephropathy
  NCT02986984 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · Ohio: Columbus